Skip to main content
. 2023 Jan 6;13:1039969. doi: 10.3389/fimmu.2022.1039969

Figure 2.

Figure 2

Evaluation of the selectivity of the C1 and E5 VHHs toward CD16a and HER2 antigens by flow cytometry. (A) Evaluation of the binding of anti-CD16a (C1 clone) VHH to NK92 cells (CD16a+), neutrophils (CD16b+), and B cells (CD32b+). 3G8 mAb against CD16a/b and AT10 mAb against CD32a/b were used as positive controls. (B) Evaluation of the binding of anti-HER2 (E5 clone) VHH to HER2+ SKOV-3 and HER2¯ MDA-MB-231 cancer cells. Trastuzumab and Pertuzumab were used as the positive controls. This figure shows the selectivity of C1 VHH toward NK cells (not neutrophils-NA1 or B cells) and E5 VHH toward HER2-positive cancer cells.